CELC

AI Memo

Celcuity

As of 2026-09-11/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

PIK3CA-mutant supplemental NDA submission • 2026-09-30

Base target: $102 / p=45% prob

Biggest risk

The valuation now depends on a first commercial launch and continued regulatory execution around a concentrated lead asset. Launch uptake, reimbursement, safety, trial execution or sNDA delays could produce substantial volatility; a former 10% owner also reported large open-market sales at $102.50 on July 14. [#SEC-FORM4-2026-07-16]

Invalidation

Break below $55 or thesis failure.

What would change my mind?

FDA approval, a preferred Category 1 NCCN recommendation, positive Phase 3 mutant-cohort results and an imminent launch create multiple paths for gedatolisib to expand across second- and potentially first-line HR+/HER2- advanced breast cancer. [#SEC-8K-2026-08-13]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-11

Base target

$102

p=45%

Bull target

$135

p=30%

Bear target

$55

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

REVTORPYK commercial launch
VIKTORIA-2 first-line expansion
FDA approval, a preferred Category 1 NCCN recommendation, positive Phase 3 mutant-cohort results and an imminent launch create multiple paths for gedatolisib to expand across second- and potentially first-line HR+/HER2- advanced breast cancer.

BearKey bullets

A former 10% owner disclosed approximately 3.10 million shares of open-market sales at $102.50, which may weigh on sentiment but does not indicate operating performance.
[#SEC-FORM4-2026-07-16]
Commercial uptake, physician adoption, reimbursement and launch execution for REVTORPYK remain unproven.

WatchKey bullets

PIK3CA-mutant supplemental NDA submission

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $102 (p=45%)

Target spread vs base: +32% / -46%

Scenario probabilities

Bull Target: $135 (p=30%)Base Target: $102 (p=45%)Bear Target: $55 (p=25%)

Commentary

Primary-source tone is constructive following FDA approval, NCCN inclusion, positive mutant-cohort results and preparations for a late-third-quarter launch. The stock's $85.49 anchor is below the July insider-sale price of $102.50, signaling that meaningful execution risk remains. No sufficient social-sentiment, options-skew, short-interest or post-update analyst-revision data were supplied; the corresponding zero values denote unavailable evidence rather than neutral readings. [#SEC-8K-2026-08-13] [#SEC-FORM4-2026-07-16]

As of 2026-09-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

REVTORPYK commercial launch
VIKTORIA-2 first-line expansion

Scenarios

Bull Target (Scenario probability)

$135 / p=30% prob

Base Target (Scenario probability)

$102 / p=45% prob

Bear Target (Scenario probability)

$55 / p=25% prob

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
PIK3CA-mutant supplemental NDA submission
Management plans to submit an sNDA in the third quarter of 2026 after the Phase 3 VIKTORIA-1 mutant cohort achieved its primary endpoint. Timely submission would broaden the addressable second-line population, while delay or regulatory friction would weaken the expansion thesis. [#SEC-8K-2026-08-13]
Prob 80.00% • Move 8.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

REVTORPYK commercial launch
2026-09-30
Celcuity said it remained on track to begin shipping REVTORPYK late in the third quarter of 2026 following FDA approval for PIK3CA wild-type HR+/HER2- advanced breast cancer. Initial launch execution, physician adoption, access and reimbursement will determine whether the regulatory success converts into commercial momentum. [#SEC-8K-2026-08-13]
Prob 85% • Move 10% • Priced-in 65%

Long-term Catalysts

Months to a year

VIKTORIA-2 first-line expansion
2027-12-31
The expanded Phase 3 VIKTORIA-2 program includes evaluation in treatment-naive, endocrine-sensitive HR+/HER2- advanced breast cancer, creating longer-term first-line optionality across mutation and endocrine-sensitivity groups. This remains a development-stage opportunity subject to enrollment, efficacy, safety and regulatory risk. [#SEC-8K-2026-08-13]
Prob 50% • Move 20% • Priced-in 30%

Risks

A former 10% owner disclosed approximately 3.10 million shares of open-market sales at $102.50, which may weigh on sentiment but does not indicate operating performance. [#SEC-FORM4-2026-07-16]
Commercial uptake, physician adoption, reimbursement and launch execution for REVTORPYK remain unproven.
Dependence on gedatolisib concentrates clinical, safety, regulatory and commercial risk.
The $575 million convertible-note financing strengthens liquidity but introduces leverage and potential dilution considerations. [#SEC-8K-2026-08-13]
The planned mutant-cohort sNDA could face submission delays, review questions or a narrower-than-expected outcome.
VIKTORIA-2 expansion increases development cost and remains exposed to enrollment, efficacy and safety uncertainty.

Peers

Symbol	Summary
ELVN	A similar-market-cap biotechnology candidate useful only as a broad development-risk and financing comparator; the packet does not establish indication, asset-stage or commercial comparability.
PBLS	A similar-market-cap biopharma valuation reference, but no evidence supplied establishes it as a direct breast-cancer or commercial-launch peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-11

Loading AI feed…

Symbol

Summary

ELVN

A similar-market-cap biotechnology candidate useful only as a broad development-risk and financing comparator; the packet does not establish indication, asset-stage or commercial comparability.

PBLS

A similar-market-cap biopharma valuation reference, but no evidence supplied establishes it as a direct breast-cancer or commercial-launch peer.